TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01427348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with assistant
Description: head extension by an assistant during direct laryngoscopy
Study: NCT03751280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-004
Description: PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
Study: NCT01427348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without assistant
Description: without head extension by an assistant during direct laryngoscopy
Study: NCT02350491

Intervention type: OTHER
Intervention: Collection of biological samples
Description: collection of biologic samples ( blood and urine) befor and after woman pregnacy
Study: NCT03751280

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
Study: NCT03287947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: Oral nintedanib, taken twice daily
Study: NCT03556345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg IV every 2 weeks
Study: NCT01306409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cera, darbepoetin, epoetin-beta
Description: Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESA
Description: Sequential application of three different ESA
Study: NCT02970721

Intervention type: DRUG
Intervention: Antipsychotic
Description: Antipsychotic monotherapy
Study: NCT02350491

Intervention type: OTHER
Intervention: Collection of biological samples
Description: collection of biologic samples ( blood and urine) befor and after woman pregnacy

Intervention type: OTHER
Intervention: Collection of biological samples
Description: collection of biologic samples ( blood and urine) befor and after woman pregnacy
Study: NCT02000635

Intervention type: OTHER
Intervention: Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day
Study: NCT03357068

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acid
Description: Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
Study: NCT02970721

Intervention type: DRUG
Intervention: Antidepressant
Description: Antidepressant monotherapy

Intervention type: DRUG
Intervention: Antipsychotic and Antidepressant
Description: Polytherapy
Study: NCT01994135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference food
Description: Reference food will be used to which test food samples will be compared to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food dose 1
Description: Will contain low dose of a mixture of polyphenols in addition to the reference food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food dose 2
Description: Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
Study: NCT04728659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 MG
Description: It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran
Description: It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
Study: NCT03044951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: cryoballoon ablation：pulmonary vein isolation by cryoballoon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
Study: NCT03973125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
Study: NCT03995537

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 4 mL Heparin sample and one 2.5 mL PAXgene® sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~* between inclusion and LT in case of major clinical change~* During the pre-transplant follow-up 3 months after inclusion, for patients who have not been transplanted within 3 months after inclusion~* at day 1 after LT~* 2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times.
Study: NCT02042989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase.
Study: NCT05872633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-management intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Care-as-usual
Study: NCT04083248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility group
Description: Same as arm description
Study: NCT04527926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPuP Intervention
Description: Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of Care
Study: NCT02979873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
Study: NCT00966056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teflon nasal septal splint
Description: Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
Study: NCT04004169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation-ON
Description: Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulation-OFF
Description: No neurostimulation from the NeuroPace RNS® System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation-ON Active Control
Description: Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
Study: NCT02569944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder stimulation
Description: Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal bag
Description: Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
Study: NCT02595593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rib Fixation System
Description: This intervention involves a surgical procedure to affix rib plates to broken ribs
Study: NCT03078699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
Study: NCT03736434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and DASH Diet Education
Description: Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and DASH Diet Education
Description: Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education group
Description: The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education group
Description: The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
Study: NCT04693468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Isethionate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study: NCT04025073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension
Description: The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Description: The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Description: The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
Study: NCT00863096

Intervention type: BIOLOGICAL
Intervention: Gardasil
Description: HPV vaccine
Study: NCT01325168

Intervention type: DRUG
Group type: OTHER
Intervention: syntocinon nasal spray
Description: nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: syntocinon nasal spray
Description: nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)

Intervention type: DRUG
Group type: OTHER
Intervention: placebo nasal spray
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo nasal spray
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study: NCT03823261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
Study: NCT01270022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dissemination
Study: NCT03449056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: T2 - T1+1h30: High-nasal flow and salbutamol nebulization
Study: NCT01535248

Intervention type: OTHER
Intervention: Transthoracic Echocardiography
Description: Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
Study: NCT01080105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM Web based intervention + surveillance
Description: The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM web based intervention
Description: The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational website
Description: Participants will receive access to a static educational website for 12 weeks.
Study: NCT05240339

Intervention type: OTHER
Intervention: Observation of minor phenomena
Description: observation twice a year over 3 years
Study: NCT04582448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
Study: NCT04270669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E 0.5mg
Description: The patient received one treatment of RC28-E 0.5mg in the test group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E 1.0mg
Description: The patient received one treatment of RC28-E 1.0mg in the test group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E2.0mg
Description: The patient received one treatment of RC28-E 2.0mg in the test group
Study: NCT01179282

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dust mite extract or placebo
Description: intervention will be to stop study drug or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: dust mite extract or placebo
Description: intervention will be to stop study drug or placebo
Study: NCT02271815

Intervention type: OTHER
Intervention: Oral Hygiene
Description: Oral Hygiene
Study: NCT03210675

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Polysomnography (PSG)
Description: PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Polysomnography (PSG)
Description: PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
Study: NCT02778178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine
Description: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL saline 0.9%, per side

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT03935581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate
Description: Auto Focusing (AF) echo imaging
Study: NCT03031899

Intervention type: PROCEDURE
Intervention: Biopsy
Description: rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rose Bengal
Description: the lesions stained positive were subjected to biopsy
Study: NCT02042989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase.
Study: NCT04444011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium isthePPI inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium isthePPI inhibitor
Study: NCT03031899

Intervention type: DIAGNOSTIC_TEST
Intervention: toluidine blue
Description: the lesions stained positive were subjected to biopsy
Study: NCT04444011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium isthePPI inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth is to protect the gastric mucosa